
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2015

BioScrip, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
Incorporation)

000-28740
(Commission File
Number)

05-0489664
(I.R.S. Employer
Identification No.)

100 Clearbrook Road
Elmsford, New York 10523
(Address of principal executive offices) (Zip Code)

(914) 460-1600
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On June 19, 2015, BioScrip, Inc. issued a press release announcing the completion of its exchange offer for \$200.0 million of its 8.875% Senior Notes due 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release, dated June 19, 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized.

BIOSCRIP, INC.

Date: June 19, 2015

By: /s/ Kimberlee C. Seah
Kimberlee C. Seah
Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit Number

Description

99.1

Press Release, dated June 19, 2015.

NEWS RELEASE



Contact:
Lisa Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FOR IMMEDIATE RELEASE**BIOSCRIP ANNOUNCES COMPLETION OF EXCHANGE OFFER FOR ITS 8.875% SENIOR NOTES DUE 2021**

Elmsford, NY – June 19, 2015 – BioScrip[®], Inc. (NASDAQ: BIOS) (“BioScrip”), today announced that it has completed its exchange offer (the “Exchange Offer”) of \$200,000,000 in aggregate principal amount of 8.875% Senior Notes due 2021 (the “Exchange Notes”), which have been registered under the Securities Act of 1933, as amended (the “Securities Act”), for an equal aggregate principal amount of its outstanding 8.875% Senior Notes due 2021 (the “Old Notes”) that were originally issued on February 11, 2014, in a transaction exempt from registration under the Securities Act.

As of the scheduled expiration time of 5:00 p.m., New York City time, on June 16, 2015, \$200,000,000 of the aggregate principal amount, or 100%, of the Old Notes were tendered and accepted for exchange by BioScrip.

This press release is neither an offer to purchase, nor a solicitation for acceptance of an offer to sell, any securities. The Exchange Offer was made only by means of, and pursuant to the terms of, the Prospectus, dated as of May 7, 2015 (the “Prospectus”) and the related Letter of Transmittal (the “Letter of Transmittal”). The complete terms and conditions of the Exchange Offer are set forth in the Prospectus and the Letter of Transmittal. Holders are urged to read these documents carefully.

About BioScrip, Inc.

BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion services from over 70 locations across 28 states.
